Calimmune

Calimmune Overview

Founded 2006
Founded
Status Acquired/​Merged
Employees 40
Employees
Latest Deal Type M&A
Latest Deal Amount $416M
Latest Deal Amount

Calimmune General Information

Description

Developer of a gene modification and cell delivery technology designed to translate the promise of gene therapy into effective and accessible products that have the power to restore health and improve lives. The company's gene modification and cell delivery technology works by genetically modifying patients' own cells to shield and strengthen their immune system and create enduring and life-long protection for individuals living with a broad range of debilitating and currently incurable diseases, enabling physicians to address the unique needs of individuals at different stages of HIV infection and with various treatment histories.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Primary Office
  • 5151 East Broadway Boulevard
  • Suite 1020
  • Tucson, AZ 85711
  • United States
+1 (310) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Calimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 11-Sep-2017 $416M 000.00 00000 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series C) 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 27-May-2015 000.00 000.00 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 01-Dec-2013 000 00.000 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC 16-Sep-2011 000 00.000 Completed Generating Revenue
2. Angel (individual) 01-Jun-2010 $50K $50K Completed Startup
1. Grant $8.28M Completed Startup

Calimmune Cap Table

To view Calimmune‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00 000.0 000.0 00 000.0 0.000
Series A 0,000,000 00.000000 00 000.0 000.0 00 000 00.000
Series 4 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series 3 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series 2 107,000 $0.001000 8% $4.94 $4.94 1x $4.94 0.85%
Series 1 188,136 $0.001000 8% $5 $5 1x $5 1.49%

Calimmune Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
ViaCyte Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 00000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000 000000000000 Venture Capital-Backed Stockholm, Sweden 0 000.00 00000000000 000.00
000000 Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000

Calimmune Executive Team (14)

Name Title Board Seat Contact Info
Jeffrey Bartlett Ph.D Chief Scientific Officer
James Sullivan Ph.D Director
Salim Yazji MD Chief Medical Officer & Executive Vice President
Inder Verma Ph.D Co-Founder & Scientific Advisor
Irvin Chen Ph.D Co-Founder & Scientific Advisor

3 Former Executives

Calimmune Board Members (8)

To view Calimmune‘s full board member team, request access »
Name Representing Role Since
David Baltimore Ph.D Self Co-Founder & Co-Chairman 000 0000
Harry George III Self Board Member 000 0000
Jon Faiz Kayyem Ph.D Calimmune Board Member and Co-Founder 000 0000
Scott Greer Self Co-Chairman 000 0000

4 Former Board Members

Calimmune Former Investors (8)

To view Calimmune‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
California Institute for Regenerative Medicine Government 000 0000 000000 0
Cycad Group Venture Capital Minority 000 0000 000000 0
DVI Equity Partners Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial